Molecular design for enhancement of ocular penetration

Journal of Pharmaceutical Sciences

Volumn 97, Issue 7, 2008, Pages 2462-2496

  Shirasaki, Yoshihisa ^a  

^a SENJU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Drug design; Epithelial delivery permeability; Permeability; Solubility; Structure property relationship (SPR); Tissue partition

Indexed keywords

6 HYDROXY 2 BENZOTHIAZOLESULFONAMIDE; 6 HYDROXY 2 BENZO[B]THIOPHENESULFONAMIDE; 6 PIVALOYLOXY 2 BENZOTHIAZOLESULFONAMIDE; ACEBUTOLOL; ACETAZOLAMIDE; ACICLOVIR DERIVATIVE; AL 4623A; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRINZOLAMIDE; BUFURALOL; BUNOLOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; ETHOXZOLAMIDE; GANCICLOVIR; HYDROCORTISONE; L 654 230; LEVOBUNOLOL; METHAZOLAMIDE; METIPRANOLOL; NONSTEROID ANTIINFLAMMATORY AGENT; PENBUTOLOL; PILOCARPINE; PROPRANOLOL; SEZOLAMIDE; STEROID; TILISOLOL; TIMOLOL; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC REACTION; AQUEOUS SOLUTION; AREA UNDER THE CURVE; DIFFUSION; DRUG ABSORPTION; DRUG DESIGN; DRUG FORMULATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG WITHDRAWAL; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; LIPOPHILICITY; NONHUMAN; OCULAR BLOOD VESSEL; PHYSICAL CHEMISTRY; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 52049087662     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21200     Document Type: Review

References (165)

1. Kempf DJ, Sham HL, Marsh KC, Flentge CA, Betebenner D, Green BE, McDonald E, Vasavanonda S, Saldivar A, Wideburg NE, Kati WM, Ruiz L, Zhao C, Fino L, Patterson J, Molla A, Plattner JJ, Norbeck DW. 1998. Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy. J Med Chem 41:602-617.
2. Arrowsmith JE, Campbell SF, Cross PE, Stubbs JK, Burges RA, Gardiner DG, Blackburn KJ. 1986. Long-acting dihydropyridine calcium antagonists. 1.2-Alkoxymethyl derivatives incorporating basic substituents. J Med Chem 29:1696-1702.
3. Smith DA, Jones BC, Walker DK. 1996. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics. Med Res Rev 16:243-266.
4. Lin J, Sahakian DC, de Morais SM, Xu JJ, Polzer RJ, Winter SM. 2003. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. Curr Top Med Chem 3:1125-1154.
5. Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW. 2005. Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Curr Top Med Chem 5:1033-1038.
6. Clark RD, Wolohan PR. 2003. Molecular design and bioavailability. Curr Top Med Chem 3:1269-1288.
7. Schwardt O, Kolb H, Ernst B. 2003. Drug discovery today. Curr Top Med Chem 3:1-9.
8. Thompson TN. 2001. Optimization of metabolic stability as a goal of modern drug design. Med Res Rev 21:412-449.
9. Kumar GN, Surapaneni S. 2001. Role of drug metabolism in drug discovery and development. Med Res Rev 21:397-411.
10. Lipinski CA, Lombardo F, Dominy BW, Feenesey PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Delivery Rev 46:3-26.
11. Gombar VK, Silver IS, Zhao Z. 2003. Role of ADME characteristics in drug discovery and their in silico evaluation: In silico screening of chemicals for their metabolic stability. Curr Top Med Chem 3:1205-1225.
12. Darvas F, Keseru G, Papp A, Dorman G, Urge L, Krajcsi P. 2002. In Silico and Ex silico ADME approaches for drug discovery. Curr Top Med Chem 2:1287-1304.
13. van De Waterbeemd H, Smith DA, Beaumont K, Walker DK. 2001. Property-based design: Optimization of drug absorption and pharmacokinetics. J Med Chem 44:1313-1333.
14. Kola I, Landis J. 2004. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711-714.
15. Blake JF. 2005. Identification and evaluation of molecular properties related to preclinical optimization and clinical fate. Med Chem 1:649-655.
16. Majumdar S, Mitra AK. 2006. Chemical modification and formulation approaches to elevated drug transport across cell membranes. Expert Opin Drug Deliv 3:511-527.
17. Lee VHL, Li VHK. 1989. Prodrugs for improved ocular drug delivery. Adv Drug Deliv Rev 3:1-38.
18. Sugrue MF. 1996 The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor. J Ocul Pharmacol Ther 12:363-376.
19. Resul B, Stjernschantz J, Selen G, Bito L. 1997. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 41:S47-S52.
20. Bodor N, Buchwald P. 2005. Ophthalmic drug design based on the metabolic activity of the eye: Soft drugs and chemical delivery systems. AAPS J 7:E820-E833.
21. Mannermaa E, Vellonen KS, Urtti A. 2006. Drug transport in corneal epithelium and blood-retina barrier: Emerging role of transporters in ocular pharmacokinetics. Adv Drug Deliv Rev 58:1136-1163.
22. Urtti A. 2006. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 58:1131-1135.
23. Raghava S, Hammond M, Kompella UB. 2004. Periocular routes for retinal drug delivery. Expert Opin Drug Deliv 1:99-114.
24. Ghate D, Edelhauser HF. 2006. Ocular drug delivery. Expert Opin Drug Deliv 3:275-287.
25. Lee VHL. 1993. Precorneal, corneal, and postcorneal factors. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker. pp. 59-81.
26. Hosoya K, Lee VHL, Kim KJ. 2005. Roles of the conjunctiva in ocular drug delivery: A review of conjunctival transport mechanisms and their regulation. Eur J Pharm Biopharm 60:227-240.
27. Sasaki H, Yamamura K, Mukai T, Nishida K, Nakamura J, Nakashima M, Ichikawa M. 1999. Enhancement of ocular drug penetration. Crit Rev Ther Drug Carrier Syst 16:85-146.
28. Klyce SD, Crosson CE. 1985. Transport processes across the rabbit corneal epithelium: A review. Curr Eye Res 4:323-331.
29. Dey S, Patel J, Anand BS, Jain-Vakkalagadda B, Kaliki P, Pal D, Ganapathy V, Mitra AK. 2003. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invet Ophthalmol Vis Sci 44:2909-2918.
30. Attar M, Shen J, Ling KH, Tang-Liu D. 2005. Ophthalmic drug delivery considerations at the cellular level: Drug-metabolising enzymes and transporters. Expert Opin Drug Deliv 2:891-908.
31. Karla PK, Pal D, Quinn T, Mitra AK. 2006. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux. Int J Pharm 336:12-21.
32. +-dependent cationic and neutral amino acid transporter, B(0,+), in human and rabbit cornea. Mol Pharm 1:338-346.
33. +-independent large neutral amino acid transporter, LAT1, in human and rabbit cornea. Invest Ophthalmol Vis Sci 44:2919-2927.
34. Majumdar S, Tirucherai GS, Pal D, Mitra AK. 2003. Functional differences in nucleoside and nucleobase transporters expressed on the rabbit corneal epithelial cell line (SIRC) and isolated rabbit cornea. AAPS Pharm Sci 5:E15.
35. Hamalainen KM, Kananen K, Auriola S, Kontturi K, Urtti A. 1997. Characterization of paracellular and aqueous penetration routes in cornea, conjunctiva, and sclera. Invest Ophthalmol Vis Sci 38:627-634.
36. Schoenwald RD. 1993. Chemical delivery systems with enhanced pharmacokinetic properties. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker. pp. 307-330.
37. Schoenwald RD, Ward RL. 1978. Relationship between steroid permeability across excised rabbit cornea and octanol-water partition coefficients. J Pharm Sci 67:786-788.
38. Schoenwald RD, Huang HS. 1983. Corneal penetration behavior of beta-blocking agents I: Physiochemical factors. J Pharm Sci 72:1266-1272.
39. Urtti A, Salminen L. 1993. Animal pharmacokinetic studies. In: Mitra AK, editor. Ophthalmic drug delivery systems. New York: Marcel Dekker. pp. 121-136.
40. Schoenwald RD, Houseman JA. 1982. Disposition of cyclophosphamide in the rabbit and human cornea. Biopharm Drug Dispos 3:231-241.
41. Edelhauser HF, Maren TH. 1988. Permeability of human cornea and sclera to sulfonamide carbonic anhydrase inhibitors. Arch Ophthalmol 106:1110-1115.
42. Hornof M, Toropainen E, Urtti A. 2005. Cell culture models of the ocular barriers. Eur J Pharm Biopharm 60:207-225.
43. Toropainen E, Ranta VP, Vellonen KS, Palmgren J, Talvitie A, Laavola M, Suhonen P, Hamalainen KM, Auriola S, Urtti A. 2003. Paracellular and passive transcellular permeability in immortalized human corneal epithelial cell culture model. Eur J Pharm Sci 20:99-106.
44. Kawazu K, Shiono H, Tanioka H, Ota A, Ikuse T, Takashina H, Kawashima Y. 1998. Beta adrenergic antagonist permeation across cultured rabbit corneal epithelial cells grown on permeable supports. Curr Eye Res 17:125-131.
45. Reichl S, Bednarz J, Muller-Goymann CC. 2004. Human corneal equivalent as cell culture model for in vitro drug permeation studies. Br J Ophthalmol 88:560-565.
46. Civiale C, Bucaria F, Piazza S, Peri O, Miano F, Enea V. 2004. Ocular permeability screening of dexamethasone esters through combined cellular and tissue systems. J Ocul Pharmacol Ther 20:75-84.
47. Ranta VP, Laavola M, Toropainen E, Vellonen KS, Talvitie A, Urtti A. 2003. Ocular pharmacokinetic modeling using corneal absorption and desorption rates from in vitro permeation experiments with cultured corneal epithelial cells. Pharm Res 20:1409-1416.
48. Kawazu K, Yamada K, Nakamura M, Ota A. 1999. Characterization of cyclosporin A transport in ultured rabbit corneal epithelial cells: P-glycoprotein transport activity and binding to cyclophilin. Invest Ophthalmol Vis Sci 40:1738-1744.
49. Dey S, Patel J, Anand BS, Jain-Vakkalagadda B, Kaliki P, Pal D, Ganapathy V, Mitra AK. 2003. Molecular evidence and functional expression of P-glycoprotein (MDR1) in human and rabbit cornea and corneal epithelial cell lines. Invest Ophthalmol Vis Sci 44:2909-2918.
50. Karla PK, Pal D, Mitra AK. 2007. Molecular evidence and functional expression of multidrug resistance associated protein (MRP) in rabbit corneal epithelial cells. Exp Eye Res 84:53-60.
51. Becker U, Ehrhardt C, Daum N, Baldes C, Schaefer UF, Ruprecht KW, Kim KJ, Lehr CM. 2007. Expression of ABC-transporters in human corneal tissue and the transformed cell line, HCE-T. J Ocul Pharmacol Ther 23:172-181.
52. Tak RV, Pal D, Gao H, Dey S, Mitra AK. 2001. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J Pharm Sci 90:1505-1515.
53. Brechue WF, Maren TH. 1993. pH and drug ionization affects ocular pressure lowering of topical carbonic anhydrase inhibitors. Invest Ophthalmol Vis Sci 34:2581-2587.
54. Tang-Liu DD, Liu S. 1987. Relationship between the ocular and systemic disposition of flurbiprofen: The effect of altered protein dynamics at steady state. J Pharmacokinet Biopharm 15:387-397.
55. Sugrue MF, Gautheron P, Mallorga P, Nolan TE, Graham SL, Schwam H, Shepard KL, Smith RL. 1990. L-662,583 is a topically effective ocular hypotensive carbonic anhydrase inhibitor in experimental animals. Br J Pharmacol 99:59-64.
56. Maren TH, Jankowska L, Sanyal G, Edelhauser HF. 1983. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res 36:457-479.
57. Lippa EA. 1991. Topical carbonic anhydrase inhibitors. In: Dodgson SJ, Tashian RE, Gros G, Carter ND, editors. The carbonic anhydrases: Cellular physiology and molecular genetics. New York and London: Plenum Press, pp. 171-181.
58. Supuran CT, Scozzafava A, Casini A. 2003. Carbonic anhydrase inhibitors. Med Res Rev 23:146-189.
59. Supuran CT, Vullo D, Manole G, Casini A, Scozzafava A. 2004. Designing of novel carbonic anhydrase inhibitors and activators. Curr Med Chem Cardiovasc Hematol Agents 2:49-68.
60. DeSantis L. 2000. Preclinical overview of brinzo-lamide. Surv Ophthalmol 44:S119-S129.
61. Schoenwald RD, Eller MG, Dixson JA, Barfknecht CF. 1984. Topical carbonic anhydrase inhibitors. J Med Chem 27:810-812.
62. Wei CP, Anderson JA, Leopold I. 1978. Ocular absorption and metabolism of topically applied epinephrine and a dipivalyl ester of epinephrine. Invest Ophthalmol Vis Sci 17:315-321.
63. Woltersdorf OW Jr, Schwam H, Bicking JB, Brown SL, deSolms SJ, Fishman DR, Graham SL, Gautheron PD, Hoffman JM, Larson RD, Lee WS, Mishelson SR, Robb CM, Share NN, Shepard KL, Smith AM, Smith RL, Sondey JM, Strohmaier KM, Sugrue MF, Viader MP. 1989. Topically active carbonic anhydrase inhibitors. 1. O-acyl derivatives of 6-hydroxybenzothiazole-2-sulfonamide. J Med Chem 32:2486-2492.
64. Graham SL, Shepard KL, Anderson PS, Baldwin JJ, Best DB, Christy ME, Freedman MB, Gautheron P, Habecker CN, Hoffman JM. 1989. Topically active carbonic anhydrase inhibitors. 2. Benzo[b]thiophenesulfonamide derivatives with ocular hypotensive activity. J Med Chem 32: 2548-2554.
65. Grove J, Gautheron P, Plazonnet B, Sugrue MF. 1988. Ocular distribution studies of the topical carbonic anhydrase inhibitors L-643,799 and L-650,719 and related alkyl prodrugs. J Ocul Pharmacol Ther 4:279-290.
66. Ponticello GS, Freedman MB, Habecker CN, Lyle PA, Schwam H, Varga SL, Christy ME, Randall WC, Baldwin JJ. 1987. Thienothiopyran-2-sulfonamides: A novel class of water-soluble carbonic anhydrase inhibitors. J Med Chem 30:591-597.
67. Baldwin JJ, Ponticello GS, Anderson PS, Christy ME, Murcko MA, Randall WC, Schwam H, Sugrue MF, Springer JP, Gautheron P, Grove J, Mallrga P, Viader MP, McKeever BM, Navia MA. 1989. Thienothiopyran-2-sulfonamides: Novel topically active carbonic anhydrase inhibitors for the treatment of glaucoma. J Med Chem 32:2510-2513.
68. Maren TH, Jankowska L, Sanyal G, Edelhauser HF. 1983. The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretion. Exp Eye Res 36:457-479.
69. Scozzafava A, Menabuoni L, Mincione F, Supuran CT. 2002. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino-polycar-boxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. J Med Chem 45:1466-1476.
70. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. 1999. Carbonic anhydrase inhibitors. Synthesis of water-soluble, topically effective, intraocular pressure-lowering aromatic/heterocyclic sulfonamides containing cationic or anionic moieties: Is the tail more important than the ring? J Med Chem 42:2641-2650.
71. Scozzafava A, Briganti F, Mincione G, Menabuoni L, Mincione F, Supuran CT. 1999. Carbonic anhy- rase inhibitors: Synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. J Med Chem 42:3690-3700.
72. Supuran CT, Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G. 1999. Carbonic anhydrase inhibitors. Part 71. Synthesis and ocular pharmacology of a new class of water-soluble, topically effective intraocular pressure lowering sulfonamides incorporating picolinoyl moieties. Eur J Pharm Sci 8:317-328.
73. Scozzafava A, Menabuoni L, Mincione F, Briganti F, Mincione G, Supuran CT. 2000. Carbonic anhydrase inhibitors: Perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. J Med Chem 43:4542-4551.
74. Sharir M, Pierce WM Jr, Chen D, Zimmerman TJ. 1994. Pharmacokinetics, acid-base balance and intraocular pressure effects of ethyloxaloylazolamide - A novel topically active carbonic anhydrase inhibitor. Exp Eye Res 58:107-116.
75. Sorensen SJ, Abel SR. 1996. Comparison of the ocular beta-blockers. Ann Pharmacother 30:43-54.
76. Huang HS, Schoenwald RD, Lach JL. 1983. Corneal penetration behavior of beta-blocking agents II: Assessment of barrier contributions. J Pharm Sci 72:1272-1279.
77. Wang W, Sasaki H, Chien DS, Lee VH. 1991. Lipophilicity influence on conjunctival drug penetration in the pigmented rabbit: A comparison with corneal penetration. Curr Eye Res 10:571-579.
78. Kawazu K, Oshita A, Nakamura T, Nakashima M, Ichikawa N, Sasaki H. 2006. Transport of acebutolol through rabbit corneal epithelium. Biol Pharm Bull 29:846-849.
79. Raub TJ. 2006. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharm 3:3-25.
80. Huang HS, Schoenwald RD, Lach JL. 1983. Corneal penetration behavior of beta-blocking agents III: In vitro-in vivo correlations. J Pharm Sci 72:1279-1281.
81. Ros FE, Innmee HC, Van Zwieten PA. 1979. Ocular penetration of β-adrenergic blocking agents. An experimental study with atenolol, metoprolol, timolol and propranolol. Doc Ophthalmol 48:291-301.
82. Vareilles P, Silverstone D, Plazonnet B, Le Douarec JC, Sears ML, Stone CA. 1977. Comparison of the effects of timolol and other adrenergic agents on intraocular pressure in the rabbit. Invest Ophthalmol Vis Sci 16:987-996.
83. Chen CC, Anderson J, Shackleton M, Attard J. 1987. The disposition of bunolol in the rabbit eye. J Ocul Pharmacol 3:149-157.
84. Chen CC, Koda RT, Shackleton M. 1988. The ocular distribution of bunolol in the eyes of albino and pigmented rabbits. J Ocul Pharmacol 4:37-42.
85. Acheampong AA, Breau A, Shackleton M, Tang-Liu DD. 1995. Comparison of concentration-time profiles of levobunolol and timolol in anterior and posterior ocular tissues of albino rabbit. J Ocul Pharmacol Ther 11:489-501.
86. Chien DS, Bundgaard H, Lee VH. 1988. Influence of corneal epithelial integrity on the penetration of timolol prodrugs. J Ocul Pharmacol 4:137-146.
87. Sasaki H, Igarashi Y, Nishida K, Nakamura J. 1993. Ocular delivery of the β-blocker, tilisolol, through the prodrug approach. Int J Pharm 93:49-60.
88. El-Koussi AA, Bodor N. 1989. Formation of pro-pranolol in the iris-ciliary body from its propranolol ketoxime precursor. Int J Pharm 53:189-194.
89. Sugrue MF. 1997. New approaches to antiglaucoma therapy. J Med Chem 40:2793-2809.
90. Chien DS, Homsy JJ, Gluchowski C, Tang-Liu DD. 1990. Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342,and clonidine in rabbit eyes. Curr Eye Res 9:1051-1059.
91. 2- adrenergic agonists. J Med Chem 40:18-23.
92. 2 adrenoceptor agonist. J Med Chem 39:3533-3538.
93. Camras CB, Aim A. 1997. Initial clinical studies with prostaglandins their analogues. Surv Ophthalmol 41:S61-S68.
94. 2α,-l-iso-propyl ester. Exp Eye Res 44:217-226.
95. 2α, esters across cornea in vitro. Int J Pharm 29:259-266.
96. 2α, and its isopropyl ester in vitro. Int J Pharm 37:27-32.
97. 2α, prodrugs in rabbit cornea and conjunctiva. J Pharm Sci 86:1180-1186.
98. Madhu C, Rix P, Nguyen T, Chien DS, Woodward DF, Tang-Liu DD. 1998. Penetration of natural prostaglandins and their ester prodrugs and analogs across human ocular tissues in vitro. J Ocul Pharmacol Ther 14:389-399.
99. 2α, ester prodrugs and receptor selective prostaglandin analogs. J Ocul Pharmacol 10:177-193.
100. Higaki K, Takeuchi M, Nakano M. 1996. Estimation and enhancement of in vitro corneal transport of S-1033, a novel antiglaucoma medication. Int J Pharm 132:165-173.
101. Ueno R, Yoshida S, Deguchi T, Kato I, Oda T, Hayashi Y, Kuno S. 1992. The intraocular pressure lowering effects of UF-021, a novel prostaglandin related compound, in animals. Nippon Ganka Gakkai Zasshi 96:462-468.
102. Azuma I, Masuda K, Kitazawa Y, Takase M, Yamamura H. 1993. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn J Ophthalmol 37:514-525.
103. Resul B, Stjernschantz J, Selen G, Bito L. 1997. Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids. Surv Ophthalmol 41:S47-S52.
104. Babiole M, Wilhelm F, Schoch C. 2001. In vitro corneal permeation of unoprostone isopropyl (UI) and its metabolism in the isolated pig eye. J Ocul Pharmacol Ther 17:159-172.
105. Resul B, Stjernschantz J, No K, Liljebris C, Selen G, Astin M, Karlsson M, Bito LZ. 1993. Phenyl-substituted prostaglandins: Potent and selective antiglaucoma agents. J Med Chem 36:243-248.
106. 2α, isopropyl ester: Potential antiglaucoma agents. J Med Chem 38:289-304.
107. Hellberg MR, McLaughlin MA, Sharif NA, DeSantis L, Dean TR, Kyba EP, Bishop JE, Klimko PG, Zinke PW, Selliah RD, Barnes G, DeFaller J, Kothe A, Landry T, Sullivan EK, Andrew R, Davis AA, Silver L, Bergamini MV, Robertson S, Weiner AL, Sallee VL. 2002. Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist. Surv Ophthalmol 47:S13-S33.
108. Basu S, Sjoquist B, Stjernschantz J, Resul B. 1994. Corneal permeability to and ocular metabolism of phenyl substituted prostaglandin esters in vitro. Prostaglandins Leukot Essent Fatty Acids 50: 161-168.
109. Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ. 2001. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol 45:S337-S345.
110. Maxey KM, Johnson JL, LaBrecque J. 2002. The hydrolysis of bimatoprost in corneal tissue generates a potent prostanoid FP receptor agonist. Surv Ophthalmol 47:S34-S40.
111. Stroman DW, Dajcs JJ, Cupp GA, Schlech BA. 2005. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol 50:S16-S31.
112. Robertson SM, Curtis MA, Schlech BA, Rusinko A, Owen GR, Dembinska O, Liao J, Dahlin DC. 2005. Ocular pharmacokinetics of moxifloxacin after topical treatment of animals and humans. Surv Ophthalmol 50:S32-S45.
113. Fukuda M, Sasaki H, Ohashi Y. 2006. Intraocular penetration of moxifloxacin ophthalmic solution in rabbit eyes - Calculation of maximum drug concentration in aqueous. Atarashii Ganka (J Eye) 23:1353-1357.
114. max). Atarashii Ganka (J Eye) 21:1109-1112.
115. max. Atarashii Ganka (J Eye) 12:787-790.
116. Kaufman HE, Varnell ED, Centifanto YM, Rheinstrom SD. 1978. Effect of 9-(2-hydroxyeth-oxymethyDguanine on herpesvirus-induced kera-titis and iritis in rabbits. Antimicrob Agents Chemother 14:842-845.
117. Smith KO, Galloway KS, Kennell WL, Ogilvie KK, Radatus BK. 1982. A new nucleoside analog, 9-[[2-hydroxy-l-(hydroxymethyl)ethoxyl]methyl]gua-nine, highly active in vitro against herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 22:55-61.
118. Hughes PM, Mitra AK. 1993. Effect of acylation on the ocular disposition of acyclovir. II: Corneal permeability and anti-HSV 1 activity of 2'-esters in rabbit epithelial keratitis. J Ocul Pharmacol 9:299-309.
119. Tirucherai GS, Dias C, Mitra AK. 2002. Corneal permeation of ganciclovir: Mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther 18:535-548.
120. Patel K, Trivedi S, Luo S, Zhu X, Pal D, Kern ER, Mitra AK. 2005. Synthesis, physicochemical properties and antiviral activities of ester prodrugs of ganciclovir. Int J Pharm 305:75-89.
121. Hughes PM, Krishnamoorthy R, Mitra AK. 1993. Effect of acylation on the ocular disposition of acyclovir. I: Synthesis, physicochemical properties, and antiviral activity of 2'-esters. J Ocul Pharmacol 9:287-297.
122. Anand BS, Katragadda S, Gunda S, Mitra AK. 2006. In vivo ocular pharmacokinetics of acyclovir dipeptide ester prodrugs by microdialysis in rabbits. Mol Pharm 3:431-440.
123. Tirucherai GS, Dias C, Mitra AK. 2002. Corneal permeation of ganciclovir: Mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. J Ocul Pharmacol Ther 18:535-548.
124. Dias CS, Anand BS, Mitra AK. 2002. Effect of mono- and di-acylation on the ocular disposition of ganciclovir: Physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs. J Pharm Sci 91:660-668.
125. Tak RV, Pal D, Gao H, Dey S, Mitra AK. 2001. Transport of acyclovir ester prodrugs through rabbit cornea and SIRC-rabbit corneal epithelial cell line. J Pharm Sci 90:1505-1515.
126. Hughes PM, Mitra AK. 1993. Effect of acylation on the ocular disposition of acyclovir. II: Corneal permeability and anti-HSV 1 activity of 2'-esters in rabbit epithelial keratitis. J Ocul Pharmacol 9:299-309.
127. Purifoy DJ, Beauchamp LM, de Miranda P, Ertl P, Lacey S, Roberts G, Rahim SG, Darby G, Krenitsky TA, Powell KL. 1993. Review of research leading to new anti-herpesvirus agents in clinical development: Valaciclovir hydrochlor-ide (256U, the L-valyl ester of acyclovir) and 882C, a specific agent for varicella zoster virus. J Med Virol Supl 1:139-145.
128. Jung D, Dorr A. 1999. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropo-sitive subjects. J Clin Pharmacol 39:800-804.
129. Anand B, Nashed Y, Mitra A. 2003. Novel dipeptide prodrugs of acyclovir for ocular herpes infections: Bioreversion, antiviral activity and transport across rabbit cornea. Curr Eye Res 26:151-163.
130. Majumdar S, Nashed YE, Patel K, Jain R, Itahashi M, Neumann DM, Hill JM, Mitra AK. 2005. Dipeptide monoester ganciclovir prodrugs for treating HSV-1-induced corneal epithelial and stromal keratitis: In vitro and in vivo evaluations. J Ocul Pharmacol Ther 21:463-474.
131. Anand BS, Mitra AK. 2002. Mechanism of corneal permeation of L-valyl ester of acyclovir: Targeting the oligopeptide transporter on the rabbit cornea. Pharm Res 19:1194-1202.
132. Gunda S, Hariharan S, Mitra AK. 2006. Corneal absorption and anterior chamber pharmacokinetics of dipeptide monoester prodrugs of ganci-clovir (GCV): In vivo comparative evaluation of these prodrugs with Val-GCV and GCV in rabbits. J Ocul Pharmacol Ther 22:465-476.
133. Agata M, Abe T, Kon M, Tanaka M, Kimura T, Nakajima A. 1983. Effect of topical diclofenac sodium, a non-steroidal anti-inflammatory drug, on various ocular inflammatory models in animals. Nippon Ganka Gakkai Zasshi 87:19-28.
134. Ogawa T, Sakaue T, Terai T, Fukiage C. 1995. Effects of bromfenac sodium, non-steroidal anti-inflammatory drug, on acute ocular inflammation. Nippon Ganka Gakkai Zasshi 99:406-411.
135. Tang-Liu DD, Liu SS, Weinkam RJ. 1984. Ocular and systemic bioavailability of ophthalmic flurbi-profen. J Pharmacokinet Biopharm 12:611-626.
136. Ogawa T, Ohara K, Ohira M. 1988. Effects of pre-instilled mydriatics on the intraocular concentration and anti-inflammatory action of topical 0.1% pranoprofen. Nippon Ganka Gakkai Zasshi 92: 1510-1519.
137. Rooks WH II, Maloney PJ, Shott LD, Schuler ME, Sevelius H, Strosberg AM, Tanenbaum L, Tomolonis AJ, Wallach MB, Waterbury D, et al. 1985. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs Exp Clin Res 11:479-492.
138. Walsh DA, Moran HW, Shamblee DA, Welstead WJ Jr, Nolan JC, Sancilio LF, Graff G. 1990. Antiinflammatory agents. 4. Syntheses and biological evaluation of potential prodrugs of 2-amino-3-benzoylbenzeneacetic acid and 2-amino-3-(4-chlorobenzoyl)benzeneacetic acid. J Med Chem 33:2296-2304.
139. Ke TL, Graff G, Spellman JM, Yanni JM. 2000. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioacti-vation and permeation of external ocular barriers. Inflammation 24:371-384.
140. Lindstrom R, Kim T. 2006. Ocular permeation and inhibition of retinal inflammation: An examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin 22:397-404.
141. Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM. 2000. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation 24:357-370.
142. Tang-Liu DS, Richman JB, Weinkam RJ, Takruri H. 1994. Effects of four penetration enhancers on corneal permeability of drugs in vitro. J Pharma Sci 83:85-90.
143. Musson DG, Bidgood AM, Olejnik O. 1991. Comparative corneal penetration of prednisolone sodium phosphate and prednisolone acetate in NZW rabbits. J Ocul Pharmacol 7:175-182.
144. Musson DG, Bidgood AM, Olejnik O. 1992. An in vitro comparison of the permeability of prednisolone, prednisolone sodium phosphate, and prednisolone acetate across the NZW rabbit cornea. J Ocul Pharmacol 8:139-150.
145. Civiale C, Bucaria F, Piazza S, Peri O, Miano F, Enea V. 2004. Ocular permeability screening of dexamethasone esters through combined cellular and tissue systems. J Ocul Pharmacol Ther 20:75-84.
146. Shih M, David LL, Lampi KJ, Ma H, Fukiage C, Azuma M, Shearer TR. 2001. Proteolysis by m-calpain enhances in vitro light scattering by crystallins from human and bovine lenses. Curr Eye Res 22:458-469.
147. Shearer TR, David LL, Anderson RS. 1987. Sele-nite cataract: A review. Curr Eye Res 6:289-300.
148. Sakamoto-Mizutani K, Fukiage C, Tamada Y, Azuma M, Shearer TR. 2002. Contribution of ubiquitous calpains to cataractogenesis in the spontaneous diabetic WBN/Kob rat. Exp Eye Res 75:611-617.
149. Fukiage C, Azuma M, Nakamura Y, Tamada Y, Nakamura M, Shearer TR. 1997. SJA6017, a newly synthesized peptide aldehyde inhibitor of calpain: Amelioration of cataract in cultured rat lenses. Biochim Biophys Acta 1361:304-312.
150. Nakamura M, Yamaguchi M, Sakai O, Inoue J. 2003. Exploration of cornea permeable calpain inhibitors as anticataract agents. Bioorg Med Chem 11:1371-1379.
151. Daniel-Mwambete K, Torrado S, Cuesta-Bandera C, Ponce-Gordo F, Torrado JJ. 2004. The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. Int J Pharm 272:29-36.
152. Calpena AC, Blanes C, Moreno J, Obach R, Domenech J. 1994. A comparative in vitro study of transdermal absorption of antiemetics. J Pharm Sci 83:29-33.
153. Hui HW, Robinson JR. 1986. Effect of particle dissolution rate on ocular drug bioavailability. J Pharm Sci 75:280-287.
154. Nakamura M, Miyashita H, Yamaguchi M, Shirasaki Y, Nakamura Y, Inoue J. 2003. Novel 6-hydroxy-3-morpholinones as cornea permeable calpain inhibitors. Bioorg Med Chem 11:5449-5460.
155. Jain R, Majumdar S, Nashed Y, Pal D, Mitra AK. 2004. Circumventing P-glycoprotein-mediated cel lular efflux of quinidine by prodrug derivatization. Mol Pharm 1:290-299.
156. Katragadda S, Talluri RS, Mitra AK. 2006. Modulation of P-glycoprotein-mediated efflux by prodrug derivatization: An approach involving peptide transporter-mediated influx across rabbit cornea. J Ocul Pharmacol Ther 22:110-120.
157. Shirasaki Y, Yamaguchi M, Miyashita H. 2006. Retinal penetration of calpain inhibitors in rats after oral administration. J Ocul Pharmacol Ther 22:417-424.
158. Shirasaki Y, Miyashita H, Yamaguchi M, Inoue J, Nakamura M. 2005. Exploration of orally available calpain inhibitors: Peptidyl a-ketoamides containing an amphiphile at P3 site. Bioorg Med Chem 13:4473-4484.
159. Goodwin JT, Conradi RA, Ho NF, Burton PS. 2001. Physicochemical determinants of passive membrane permeability: Role of solute hydrogen-bonding potential and volume. J Med Chem 44:3721-3729.
160. Pajouhesh H, Lenz GR. 2005. Medicinal chemical properties of successful central nervous system drugs. NeuroRX 2:541-553.
161. Ettmayer P, Amidon GL, Clement B, Testa B. 2004. Lessons learned from marketed and in-vestigational prodrugs. J Med Chem 47:2393-2404.
162. Balant LP, Doelker E, Buri P. 1990. Prodrugs for the improvement of drug absorption via different routes of administration. Eur J Drug Metab Phar-macokinet 15:143-153.
163. Anand BS, Dey S, Mitra AK. 2002. Current pro-drug strategies via membrane transporters/receptors. Expert Opin Biol Ther 2:607-620.
164. Salvi A, Carrupt PA, Mayer JM, Testa B. 1997. Esterase-like activity of human serum albumin toward prodrug esters of nicotinic acid. Drug Metab Dispos 25:395-398.
165. Venkatachalam TK, Sarquis M, Qazi S, Uckun FM. 2006. Effect of alkyl groups on the cellular hydrolysis of stavudine phosphoramidates. Bioorg Med Chem 14:6420-6433.